Barclays Issues Positive Forecast for Xencor (NASDAQ:XNCR) Stock Price

Xencor (NASDAQ:XNCR) had its target price increased by Barclays from $26.00 to $27.00 in a report published on Thursday morning,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock.

Other analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. dropped their price objective on shares of Xencor from $20.00 to $18.00 and set an “overweight” rating for the company in a research note on Thursday, November 6th. Royal Bank Of Canada upped their price target on Xencor from $18.00 to $19.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Cantor Fitzgerald increased their price target on Xencor from $40.00 to $42.00 and gave the company an “overweight” rating in a report on Thursday, November 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xencor in a research note on Monday, December 29th. Finally, Wedbush restated an “outperform” rating and issued a $26.00 target price on shares of Xencor in a report on Thursday, November 6th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Xencor presently has a consensus rating of “Moderate Buy” and an average target price of $25.00.

Xencor Stock Performance

Shares of XNCR stock opened at $13.55 on Thursday. Xencor has a fifty-two week low of $6.92 and a fifty-two week high of $18.69. The stock’s fifty day moving average is $13.21 and its two-hundred day moving average is $12.74. The firm has a market capitalization of $967.61 million, a P/E ratio of -10.93 and a beta of 0.98.

Xencor (NASDAQ:XNCR) last released its earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.55. The business had revenue of $28.24 million during the quarter, compared to analyst estimates of $29.97 million. Xencor had a negative net margin of 73.20% and a negative return on equity of 14.62%. The company’s revenue for the quarter was down 46.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.62) earnings per share. On average, equities analysts forecast that Xencor will post -3.68 earnings per share for the current year.

Insider Activity at Xencor

In other news, VP John R. Desjarlais sold 73,367 shares of the firm’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $15.72, for a total transaction of $1,153,329.24. Following the completion of the transaction, the vice president directly owned 236,574 shares in the company, valued at $3,718,943.28. This trade represents a 23.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Bassil I. Dahiyat sold 114,377 shares of the business’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $15.71, for a total value of $1,796,862.67. Following the completion of the sale, the chief executive officer owned 466,635 shares in the company, valued at $7,330,835.85. This represents a 19.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 4.76% of the stock is currently owned by company insiders.

Institutional Trading of Xencor

Several hedge funds have recently made changes to their positions in XNCR. Hantz Financial Services Inc. boosted its stake in shares of Xencor by 209.1% in the third quarter. Hantz Financial Services Inc. now owns 3,187 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 2,156 shares during the period. GAMMA Investing LLC lifted its holdings in Xencor by 77.1% during the 3rd quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 1,449 shares in the last quarter. Farther Finance Advisors LLC purchased a new position in Xencor in the 3rd quarter valued at approximately $44,000. Tower Research Capital LLC TRC grew its stake in shares of Xencor by 118.4% in the second quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 3,018 shares in the last quarter. Finally, Federated Hermes Inc. increased its position in shares of Xencor by 114.3% during the third quarter. Federated Hermes Inc. now owns 3,947 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 2,105 shares during the period.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.